Pharmacologically inducing regenerative cardiac cells by small molecule drugs

Wei Zhou,Kezhang He,Chiyin Wang,Pengqi Wang,Dan Wang,Bowen Wang,Han Geng,Hong Lian,Tianhua Ma,Yu Nie,Sheng Ding

DOI: https://doi.org/10.1101/2023.10.24.563872

2024-07-21

Abstract:Adult mammals, unlike some lower organisms, lack the ability to regenerate damaged hearts through cardiomyocytes (CMs) dedifferentiation into cells with regenerative capacity. Developing conditions to induce such naturally unavailable cells with potential to proliferate and differentiate into CMs, i.e., regenerative cardiac cells (RCCs), in mammals will provide new insights and tools for heart regeneration research. In this study, we demonstrate that a two-compound combination, CHIR99021 and A-485 (2C), effectively induces RCCs from human embryonic stem cell (hESC)-derived TNNT2+ CMs in vitro, as evidenced by lineage tracing experiments. Functional analysis shows that these RCCs express a broad spectrum of cardiogenesis genes and have the potential to differentiate into functional CMs, endothelial cells (ECs), and smooth muscle cells (SMCs). Importantly, similar results were observed in neonatal rat CMs both in vitro and in vivo. Remarkably, administering 2C in adult mouse hearts significantly enhances survival and improves heart function post-myocardial infarction. Mechanistically, CHIR99021 is crucial for the transcriptional and epigenetic activation of genes essential for RCC development, while A-485 primarily suppresses H3K27Ac and particularly H3K9Ac in CMs. Their synergistic effect enhances these modifications on RCC genes, facilitating the transition from CMs to RCCs. Therefore, our findings demonstrate the feasibility and reveal the mechanisms of pharmacological induction of RCCs from endogenous CMs, which could offer a promising regenerative strategy to repair injured hearts.

Cell Biology

What problem does this paper attempt to address?

The paper attempts to address the issue of inducing cardiomyocytes (CMs) in adult mammals to dedifferentiate into regenerative cardiac cells (RCCs) through drug induction. Specifically, the study aims to identify small molecule drug combinations that can prompt mature cardiomyocytes to reacquire proliferative and differentiation capabilities, thereby promoting cardiac regeneration and providing new strategies and tools for the treatment of heart disease.

The research found that the combination of two small molecule drugs, CHIR99021 and A-485 (referred to as the 2C combination), can effectively induce human embryonic stem cell-derived cardiomyocytes and neonatal rat cardiomyocytes to dedifferentiate into RCCs in vitro. These RCCs not only express a broad range of early cardiac development genes but also have the potential to differentiate into functional cardiomyocytes, endothelial cells, and vascular smooth muscle cells. More importantly, the application of the 2C combination in the hearts of adult mice significantly improved survival rates and cardiac function after myocardial infarction, suggesting that the 2C combination may provide a promising regenerative strategy for repairing damaged hearts.